UNIS - Reversal - Is this the start of a meaningful uptrend?

135 0 0
Unilife recently announced an agreement with Sanofi             to be the sole provider for a minimum of 15 years of cartridge based wearable injectors for all of Sanofi’s large dose volume drugs, excluding insulin. While the details are confidential, it is anticipated that it is for a "fast track" drug for high cholesterol, Alirocumab, which is co- developed by Sanofi             and Regeneron. It is pending FDA approval and expected to be commercialized in the June 2015 quarter.

Griffin Securities called this deal a total game changer for Unilife and indicated in its report that even average volume and new-product launches would be enough in net income to drive the stock to its $13.50 price target. They estimate this one wearable injector deal might be enough to bring in $1 billion in annual sales. Digging into their report, they forecast UNIS             to be EPS             positive in Q4 2015 (June).

This is a good company to keep on watch and get on the ground floor of a potential medical device behemoth in the making. Future earnings reports will confirm.

EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
Home Stock Screener Forex Signal Finder Cryptocurrency Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out